Phathom Pharmaceuticals, Inc. (PHAT)
| Market Cap | 889.62M +167.8% |
| Revenue (ttm) | 204.89M +150.3% |
| Net Income | -157.30M |
| EPS | -2.09 |
| Shares Out | 79.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,232,294 |
| Open | 11.46 |
| Previous Close | 11.78 |
| Day's Range | 9.74 - 11.82 |
| 52-Week Range | 2.21 - 18.31 |
| Beta | 0.61 |
| Analysts | Strong Buy |
| Price Target | 19.83 (+77.05%) |
| Earnings Date | Apr 30, 2026 |
About PHAT
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-eros... [Read more]
Financial Performance
In 2025, Phathom Pharmaceuticals's revenue was $175.11 million, an increase of 216.93% compared to the previous year's $55.25 million. Losses were -$221.25 million, -33.82% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PHAT stock is "Strong Buy." The 12-month stock price target is $19.83, which is an increase of 77.05% from the latest price.
News
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointe...
Phathom Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue more than doubled year-over-year, driven by strong VOQUEZNA adoption in gastroenterology. Covered prescriptions grew 91%, and the company maintains 2026 guidance, expecting operating profitability by Q3.
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroin...
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical ...
Phathom Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
VOQUEZNA’s focused GI strategy is driving strong revenue growth, with 2026 set as a pivotal year for profitability and cash flow. The company’s capital structure is now sustainable, and long-term growth will be supported by expanding into primary care and leveraging first-mover advantage.
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroin...
Phathom Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Leadership implemented a strategic pivot to gastroenterology, cut operating expenses by 50%, and restructured finances to support sustainable growth. The company projects strong revenue growth, targets a $1 billion market in GI, and expects exclusivity until at least 2033.
Phathom Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Focused on GI specialists, VOQUEZNA achieved rapid growth and strong persistence among patients inadequately treated by PPIs, with a clear path to $1 billion in revenue and operating profitability by 2026. Regulatory exclusivity extends to at least 2032, with lifecycle and OTC opportunities under assessment.
Phathom Pharmaceuticals Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 217% revenue growth and improved margins, driven by GI strategy and sales force execution. Enhanced capital structure and issued 2026 guidance for $320–$345 million revenue, targeting profitability by Q3 and cash flow positivity in 2027.
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 mill...
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
A strategic pivot to focus on gastroenterologists drove strong revenue growth and improved expense discipline, with profitability expected in late 2026. The company targets deep GI market penetration, leverages exclusivity extensions, and plans to launch additional GI assets before VOQUEZNA's loss of exclusivity.
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
A strategic pivot to focus on gastroenterology sales has halved operating expenses and driven revenue growth, with Q3 results and script trends suggesting outperformance. Profitability is targeted for 2026, with future growth expected from patient advocacy and potential OTC conversion.
Phathom Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
VOQUEZNA is focused on patients with persistent gastroesophageal reflux symptoms after PPI failure, with a strategic sales shift to gastroenterology driving strong growth. The company targets $1 billion in annual revenue within two to three years, supported by robust exclusivity and broad commercial coverage.
Phathom Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference
A focused GI sales strategy has driven strong revenue growth and improved financial discipline, with 3% market penetration and significant room for expansion. Physician adoption is staged and driven by patient outcomes, while Medicare access and pipeline developments support future growth.
Phathom Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
VOQUEZNA is driving strong growth by targeting gastroenterologists, with Q3 revenue up 23% and prescriptions up 28%. Operating expenses have been significantly reduced, and the company is on track for profitability in 2024. Market exclusivity extends to 2032, with further upside from ongoing EoE trials.
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
First patient dosed, with topline results expected in 2027 pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (G...
Phathom Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 saw 25% revenue growth and a 43% reduction in operating expenses, with strong execution on a GI-focused strategy and improved cash usage. Full-year guidance was raised, and the company remains on track for operating profitability in 2026, supported by robust prescription growth and disciplined cost management.
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expens...
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
FLORHAM PARK, N.J., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...